Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

New England Journal of Medicine

Volumn 346, Issue 4, 2002, Pages 225-234

  Walsh, Thomas J ^a   Pappas, Peter ^b   Winston, Drew J ^c   Lazarus, Hillard M ^d   Petersen, Finn ^e   Raffalli, John ^f   Yanovich, Saul ^g   Stiff, Patrick ^h   Greenberg, Richard ⁱ   Donowitz, Gerald ^j   Schuster, Mindy ^l   Reboli, Annette ^m   Wingard, John ⁿ   Arndt, Carola ^o   Reinhardt, John ^p   Hadley, Susan ^q   Finberg, Robert ^r   Laverdière, Michél ^s   Perfect, John ^t   Garber, Gary ^u   Fioritoni, Giuseppe ^v   Anaissie, Eli ^w   Lee, Jeanette ^k   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e UNIVERSITY OF UTAH   (United States)

^f NEW YORK MEDICAL COLLEGE   (United States)

^g VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h LOYOLA UNIVERSITY CHICAGO   (United States)

ⁱ UNIVERSITY OF KENTUCKY   (United States)

^j UNIVERSITY OF VIRGINIA   (United States)

^k NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^l UNIVERSITY OF PENNSYLVANIA   (United States)

^m Department of Anesthesiology   (United States)

ⁿ UNIVERSITY OF FLORIDA   (United States)

^o MAYO CLINIC   (United States)

^p MEDICAL CENTER OF DELAWARE   (United States)

^q BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^r DANA FARBER CANCER INSTITUTE   (United States)

^s MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^t DUKE UNIVERSITY   (United States)

^u UNIVERSITY OF OTTAWA   (Canada)

^v Ospedaliero della ASL di Pescara   (Italy)

^w UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B LIPID COMPLEX; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG INFUSION; FEBRILE NEUTROPENIA; FEMALE; HALLUCINATION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; LENGTH OF STAY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; NEPHROTOXICITY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT OUTCOME; VISUAL IMPAIRMENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMPHOTERICIN B; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; CHILD; CHRONIC DISEASE; FEMALE; FEVER; HUMANS; INFUSIONS, INTRAVENOUS; LIVER DISEASES; MALE; MIDDLE AGED; MYCOSES; NEOPLASMS; NEUTROPENIA; PROSPECTIVE STUDIES; PYRIMIDINES; TRIAZOLES;

EID: 0037165259     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200201243460403     Document Type: Article

References (37)

1. Emerging fungal pathogens in immunocompromised patients: Classification, diagnosis, and management
2. Infections with Aspergillus species
3. Nosocomial pneumonia in patients having bone marrow transplant: Attributable mortality and risk factors
4. Management of fever in patients with cancer and treatment-induced neutropenia
5. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever
6. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia
7. Empiric antifungal therapy in febrile granulocytopenic patients
8. Response to empiric amphotericin B during antileukemic therapy-induced granulocytopenia
9. Practice guidelines for the treatment of candidiasis
10. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
11. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients
12. Current and emerging azole antifungal agents
13. New investigational antifungal agents for treating invasive fungal infections
14. A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia
15. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: A pragmatic, multicentre, prospective and randomised clinical trial
16. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer
17. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: A randomized, controlled trial
18. Voriconazole for "salvage" treatment of invasive aspergillosis
19. Efficacy of safety of voriconazole (VORI) and the treatment of invasive fungal infection in children
20. Voriconazole (VORI) for the treatment of resistant and rare fungal pathogens
21. Analysis of definitions used in clinical research on invasive fungal infections: Consensus proposal for new, standardized definitions
22. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing for filamentous fungi
23. A rapid HPLC assay for voriconazole in human plasma
24. Open, randomized comparison of voriconazole (VRC) and amphotericin B (AmB) followed by other licensed antifungal therapy of invasive aspergillosis (IA)
25. In vitro activity of voriconazole against selected fungi
26. In vitro activity of the new triazole voriconazole (UK-109-496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens
27. New concepts in the pulmonary disposition of antibiotics
28. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation
29. Prognostic factors of invasive pulmonary aspergillosis in leukemic patients
30. Invasive aspergillosis: Disease spectrum, treatment practices, and outcomes
31. Risk factors for fungal infection in patients with malignant hematologic disorders: Implications for empirical therapy and prophylaxis
32. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia
33. Pulmonary toxicity during infusion of liposomal amphotericin B in two patients with acute leukemia
34. Lipid formulations of amphotericin B: Clinical efficacy and toxicities
35. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (Am Bisome) in neutropenic patients
36. Chest discomfort associated with liposomal amphotericin B: Report of three cases and review of the literature